Inhibition of mTOR down-regulates scavenger receptor, class B, type I (SR-BI) expression, reduces endothelial cell migration and impairs nitric oxide production

The mammalian target of rapamycin (mTOR) inhibiting drug rapamycin (Sirolimus) has severe side effects in patients including hyperlipidemia, an established risk factor for atherosclerosis. Recently, it was shown that rapamycin decreases hepatic LDL receptor (LDL-R) expression, which likely contribut...

Descripción completa

Detalles Bibliográficos
Autores principales: Fruhwürth, Stefanie, Krieger, Sigurd, Winter, Katharina, Rosner, Margit, Mikula, Mario, Weichhart, Thomas, Bittman, Robert, Hengstschläger, Markus, Stangl, Herbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6487575/
https://www.ncbi.nlm.nih.gov/pubmed/24713582
http://dx.doi.org/10.1016/j.bbalip.2014.03.014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6487575/
https://www.ncbi.nlm.nih.gov/pubmed/24713582
http://dx.doi.org/10.1016/j.bbalip.2014.03.014

Ejemplares similares